News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Sanofi-Aventis (France), Vical Incorporated Limb Ischemia Drug NV1FGF Fails in Late-Stage Test
September 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Sept. 22 (Bloomberg) -- Sanofi-Aventis SA said a drug that had showed promise in restoring blood vessel growth in damaged limbs was no better than a placebo in an advanced test.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
Sanofi (France)
MORE ON THIS TOPIC
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
January 13, 2026
·
3 min read
·
Nick Paul Taylor
ADCs
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
January 13, 2026
·
3 min read
·
Tristan Manalac
Collaboration
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy
January 12, 2026
·
3 min read
·
Annalee Armstrong
Drug Development
Biopharma Momentum To Propel Rare Disease, Cancer, Neuro Forward in 2026
January 12, 2026
·
6 min read
·
Heather McKenzie